Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Avanos Medical (AVNS) Finished Goods (2016 - 2025)

Avanos Medical (AVNS) has disclosed Finished Goods for 12 consecutive years, with $84.0 million as the latest value for Q4 2025.

  • Quarterly Finished Goods rose 7.28% to $84.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $84.0 million through Dec 2025, up 7.28% year-over-year, with the annual reading at $84.0 million for FY2025, 7.28% up from the prior year.
  • Finished Goods hit $84.0 million in Q4 2025 for Avanos Medical, up from $80.2 million in the prior quarter.
  • In the past five years, Finished Goods ranged from a high of $103.4 million in Q1 2023 to a low of $69.8 million in Q4 2022.
  • Historically, Finished Goods has averaged $82.8 million across 5 years, with a median of $83.0 million in 2021.
  • Biggest five-year swings in Finished Goods: dropped 20.8% in 2021 and later rose 29.57% in 2023.
  • Year by year, Finished Goods stood at $71.6 million in 2021, then dropped by 2.51% to $69.8 million in 2022, then grew by 26.79% to $88.5 million in 2023, then dropped by 11.53% to $78.3 million in 2024, then increased by 7.28% to $84.0 million in 2025.
  • Business Quant data shows Finished Goods for AVNS at $84.0 million in Q4 2025, $80.2 million in Q3 2025, and $74.3 million in Q2 2025.